Literature DB >> 11134264

Long-term results of TPMT activity monitoring in azathioprine-treated renal allograft recipients.

Eric Thervet1,2, Dany Anglicheau1,2, Nathalie Toledano2, Anne-Marie Houllier2, Laure-Hélène Noel3, Henri Kreis4, Philippe Beaune2, Christophe Legendre1.   

Abstract

Thiopurine methyltransferase (TPMT) is implicated in the metabolism of azathioprine. The consequences of differential TPMT activity induction by azathioprine on the long-term results after renal transplantation were investigated. The erythrocyte TPMT activity in 82 patients on days 0, 7, and 30 was prospectively evaluated. Because various patterns of TPMT activity variation were noted, the population was subsequently divided between inductors (n = 47) and noninductors (n = 35). Data regarding patient and graft survival and acute rejection episodes were collected. Renal allograft assessment was performed at 3 mo and 2 yr to evaluate the renal function and the histologic lesions on routine biopsies. Data regarding azathioprine-related toxicity also were collected. In a subgroup of patients (n = 19), azathioprine blood levels were determined at day 7 and day 30. The graft survival censoring death was statistically improved in TPMT inductor patients when compared with non-TPMT inductors (P < 0.05). Among TPMT inductors, an acute rejection episode was observed in 34% of the patients versus 69% among non-TPMT inductors (P = 0.002). At 3 mo, serum creatinine was significantly lower among TPMT inductors when compared with non-TPMT inductors (123.1 +/- 7.6 and 161.4 +/- 13.9 micromol/L, respectively; P = 0.01). On routine allograft biopsies at 2 yr (n = 61), grade 2 or 3 chronic lesions were present in 19% versus 25%, respectively (P = NS). At days 7 and 30, the azathioprine blood levels were higher among patients who experienced acute rejection (P < 0.02). TPMT activity induction was observed in 57% of renal transplant recipients who received azathioprine. This induction was associated with better graft outcome. The appropriate conversion from azathioprine, which is a pro-drug, into 6-mercaptopurine could explain both better graft outcome and TPMT induction. Assessing the ability of azathioprine metabolism at an individualized level before transplantation may allow a more accurate choice among the different immunosuppressive treatments.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11134264     DOI: 10.1681/ASN.V121170

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  6 in total

Review 1.  Pharmacogenetics and immunosuppressive drugs in solid organ transplantation.

Authors:  Teun van Gelder; Ron H van Schaik; Dennis A Hesselink
Journal:  Nat Rev Nephrol       Date:  2014-09-23       Impact factor: 28.314

2.  Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events.

Authors:  Jeeshan Chowdhury; Govind V Kaigala; Sudeep Pushpakom; Jana Lauzon; Alistair Makin; Alexey Atrazhev; Alex Stickel; William G Newman; Christopher J Backhouse; Linda M Pilarski
Journal:  J Mol Diagn       Date:  2007-08-09       Impact factor: 5.568

3.  Thiopurine methyltransferase activity in Spain: a study of 14,545 patients.

Authors:  Javier P Gisbert; Fernando Gomollón; Carlos Cara; Marta Luna; Yago González-Lama; José María Pajares; José Maté; Luis G Guijarro
Journal:  Dig Dis Sci       Date:  2007-03-02       Impact factor: 3.487

Review 4.  Personalization of the immunosuppressive treatment in renal transplant recipients: the great challenge in "omics" medicine.

Authors:  Gianluigi Zaza; Simona Granata; Paola Tomei; Alessandra Dalla Gassa; Antonio Lupo
Journal:  Int J Mol Sci       Date:  2015-02-17       Impact factor: 5.923

Review 5.  Thiopurine S-Methyltransferase as a Pharmacogenetic Biomarker: Significance of Testing and Review of Major Methods.

Authors:  Chingiz Asadov; Gunay Aliyeva; Kamala Mustafayeva
Journal:  Cardiovasc Hematol Agents Med Chem       Date:  2017-11-08

Review 6.  Clinical pharmacology and pharmacogenetics of thiopurines.

Authors:  Srikumar Sahasranaman; Danny Howard; Sandip Roy
Journal:  Eur J Clin Pharmacol       Date:  2008-05-28       Impact factor: 3.064

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.